Semaglutide market developments in India

3 entries over 16 days, from 16 July 2026 to 31 July 2026.

01
16 July

Sun Pharma generic semaglutide approval

Sun Pharmaceutical Industries Ltd. received approval from the South African Health Products Regulatory Authority (SAHPRA).
The approval is for the manufacture and marketing of a generic version of semaglutide injection.
The drug is indicated for the treatment of adults with inadequately controlled type 2 diabetes mellitus.
The treatment is intended to be used as an adjunct to diet and exercise.
Sun Pharma plans to launch the product in the South African market in the near future.

02
18 July

The Central Drugs Standard Control Organization (CDSCO) has approved Wegovy (semaglutide injection 2.4 mg) for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH).
Wegovy is the first and only GLP-1 receptor agonist (GLP-1 RA) approved in India for this specific indication.
The approval is intended for adults with moderate to advanced liver fibrosis.
The treatment is indicated for use in conjunction with a reduced-calorie diet and increased physical activity.
MASH is characterized by excess fat buildup in the liver, leading to chronic inflammation and liver damage.

03
31 July

Sun Pharmaceutical Industries received approval from ANVISA (Brazilian Health Regulatory Agency) to manufacture and market semaglutide injection in Brazil.
The product launch is planned in partnership with Hypera Pharma.
The drug will be available as a pre-filled, multi-dose injectable pen in two strengths: 2 mg/1.5 mL and 4 mg/3 mL.
The delivery mechanism supports flexible, once-weekly dosing.
The Brazilian semaglutide injectable market is valued at approximately $413 million based on IQVIA MAT June 2026 data.

Newest first. A story that ran for 16 days is exactly the kind the mains paper asks about as one question.

Discuss the significance of the expansion of Indian pharmaceutical companies into emerging markets like Brazil. How does the export of generic versions of high-demand drugs impact global health equity and the competitiveness of the Indian pharmaceutical sector? 150 words · 31 July
Discuss the role of the Central Drugs Standard Control Organization (CDSCO) in regulating new drug indications in India. How does the approval of novel therapies for metabolic disorders reflect the evolving landscape of public health management in the country? 150 words · 18 July
Discuss the significance of the entry of Indian pharmaceutical companies into international markets with generic versions of complex drugs for chronic conditions like type 2 diabetes. 150 words · 16 July

250words.in · https://250words.in/stories/semaglutide-market-developments-in-india